The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The last date to apply for this program is 18th January 2022
The stability is led by healthy demand in the domestic and emerging markets
Subscribe To Our Newsletter & Stay Updated
